Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Rheumatology

• Publication date

  2010-01-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10067-009-1340-7PMID 20066450
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment

  2009cited by this paper
• Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis

  2008cited by this paper
• Remission in psoriatic arthritis

  2008cited by this paper
• The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate

  2008cited by this paper
• Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

  2008cited by this paper
• Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

  2008cited by this paper
• Therapies for peripheral joint disease in psoriatic arthritis. A systematic review.

  2006cited by this paper
• Towards international guidelines for the management of psoriatic arthritis.

  2006cited by this paper
• Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

  2006cited by this paper
• Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis.

  2006cited by this paper
• Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.

  2006cited by this paper
• Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.

  2004cited by this paper
• A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.

  2003cited by this paper
• Remission in psoriatic arthritis.

  2001cited by this paper
• Comparison of disability and quality of life in rheumatoid and psoriatic arthritis.

  2001cited by this paper
• Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis.

  1992cited by this paper
• Principles of immunosuppressive therapy.

  1971cited by this paper
• Psoriatic arthritis.

  1971cited by this paper
• PSORIATIC ARTHRITIS.

  1965cited by this paper

• Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.

  2025cites this paper
• Different biologics for biological-naïve patients with psoriatic arthritis: a systematic review and network meta-analysis

  2024cites this paper
• Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis

  2024influential citation
• Role of the Gut Microbiota in Osteoarthritis, Rheumatoid Arthritis, and Spondylarthritis: An Update on the Gut–Joint Axis

  2024cites this paper
• Biological therapy in psoriatic arthritis patients with and without previous biologic experience

  2022cites this paper
• First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study

  2022cites this paper
• TNF-Alpha Class of Biologic Agents in Psoriatic Disease

  2022cites this paper
• New GRAPPA TReATmeNT RecommeNdATioNs foR PsoRiATic ARThRiTis

  2021cites this paper
• FOR P SORIATIC A RTHRITIS AND P SORIASIS

  2021cites this paper
• Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis SOLAPSO – Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society)

  2019cites this paper
• Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison.

  2019cites this paper
• A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritis.

  2019cites this paper
• Use of FDA‐Approved Medications: Biologics for Psoriatic Arthritis in Patients at an Urban Outpatient Rheumatology Clinic

  2019cites this paper
• Radiologic parameters of ankylosing spondylitis patients treated with anti-TNF-α versus nonsteroidal anti-inflammatory drugs and sulfasalazine

  2019cites this paper
• What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials

  2018cites this paper
• Dactylitis and Enthesitis in Psoriatic Arthritis : 10-Year Experience with Adalimumab in Real World Clinical Practice

  2018cites this paper
• ANTIPSORIATIC THERAPY: DISCOVERING NEW HORIZONS

  2017cites this paper
• Small molecule therapy for managing moderate to severe psoriatic arthritis

  2017cites this paper
• A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor

  2017cites this paper
• Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.

  2017influential citation
• Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders

  2017influential citation
• Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.

  2017cites this paper
• Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor α-mediated neurotoxicity.

  2017cites this paper
• Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

  2017cites this paper
• Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies

  2016cites this paper
• Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis

  2016cites this paper
• [Not Available].

  2016cites this paper
• Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.

  2016cites this paper
• A Review of Psoriasis, Therapies, and Suicide

  2016cites this paper
• Biological Agents on Psoriasis Treatment in Greece

  2016cites this paper
• Efficacy of the combined therapy with etanercept and methotrexat at the female patient with generalized pustular psoriasis and arthritis psoriasis after the therapeutic failure of two the TNF-α receptor inhibitors. Case study

  2016cites this paper
• Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis

  2016cites this paper
• Phosphodiesterase 4 inhibitors for psoriatic arthritis

  2016cites this paper
• Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA

  2015cites this paper
• Psoriatic arthritis: latest treatments and their place in therapy

  2015cites this paper
• Management of arthropathy in inflammatory bowel diseases

  2015cites this paper
• Psoriatic arthritis: current therapy and future approaches.

  2015cites this paper
• A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone

  2015cites this paper
• Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis

  2015cites this paper
• Etanercept in the treatment of psoriatic arthritis.

  2015cites this paper
• Pharmacological therapy of spondyloarthritis

  2015cites this paper
• Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies

  2015cites this paper
• Making the next steps in psoriatic arthritis management: current status and future directions

  2015cites this paper
• Ultrasound in psoriatic arthritis. Can it facilitate a best routine practice in the diagnosis and management of psoriatic arthritis?

  2015cites this paper
• Therapeutic targets in psoriatic arthritis

  2015cites this paper
• Etanercept in the Treatment of Psoriatic Arthritis

  2015cites this paper
• Efficacy of tocilizumab in a patient with refractory psoriatic arthritis

  2014cites this paper
• The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection

  2014cites this paper
• Bone: Silk, metal and bone: why take implants out?

  2014cites this paper
• Advances in the management of psoriatic arthritis

  2014cites this paper
• Treatment options for psoriatic arthritis

  2014cites this paper
• Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety

  2014influential citation
• Aiming for remission in psoriatic arthritis

  2014cites this paper
• Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options.

  2014cites this paper
• Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis

  2014cites this paper
• Clinical and Contrast-Enhanced Ultrasound Echography Outcomes in Psoriatic Arthritis Patients after One Year of Continuous Therapy with Anti-TNF Drugs

  2014cites this paper
• Advances in the management of psoriatic

  2014cites this paper
• Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective.

  2014cites this paper
• Diagnosing and treating psoriatic arthritis: an update

  2014cites this paper
• Biological therapies for spondyloarthritis

  2014cites this paper
• Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis

  2013cites this paper
• Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring

  2013cites this paper
• Recommendations for the management and treatment of psoriatic arthritis.

  2013cites this paper
• [Development of lupus erythematosus during infliximab therapy].

  2013cites this paper
• Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies

  2013cites this paper
• Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis

  2013cites this paper
• Biologics for Psoriasis and Psoriatic Arthritis ( Adalimumab , Etanercept , Golimumab , Infliximab , Ustekinumab ) National PBM Criteria for Use – Monograph with Literature

  2013cites this paper
• Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Ankylosing Spondylitis

  2013cites this paper
• MEDICAMENTOS BIOLÓGICOS UTILIZADOS EM PSORÍASE MODERADA A GRAVE - UMA REVISÃO DA EVIDÊNCIA CLÍNICA BIOLOGIC MEDICINES FOR MODERATE TO SEVERE PSORIASIS - A REVIEW OF CLINICAL EVIDENCE

  2013cites this paper
• Treatment options: biologicals

  2013cites this paper
• Recommendations of the Brazilian Society of Rheumatology Recommendations for the management and treatment of psoriatic arthritis

  2013cites this paper
• Section 2: Spondyloarthritis

  2013cites this paper
• Psoriatic arthritis: current therapy and future directions

  2013cites this paper
• Recomendações sobre diagnóstico e tratamento da artrite psoriásica

  2013cites this paper
• Evaluation eines neuen 7-Gelenke-Ultraschall-Scores zum Therapiemonitoring bei Patienten mit Rheumatoider Arthritis und Psoriasisarthritis mit Einzelgelenkanalyse

  2012cites this paper
• Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

  2012cites this paper
• Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

  2012cites this paper
• Clinical outcomes in psoriatic arthritis: A systematic literature review

  2012cites this paper
• Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe.

  2012cites this paper
• An update on the diagnosis and management of psoriatic arthritis.

  2011cites this paper
• Canadian Clinical Practice Setting : The REPArE Trial Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a

  2011cites this paper
• The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept.

  2011cites this paper
• Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a Canadian Clinical Practice Setting: The REPArE Trial

  2011cites this paper
• Psoriatic juvenile idiopathic arthritis: a tale of two subgroups

  2011cites this paper
• Psoriatic arthritis

  2010cites this paper
• How early should psoriatic arthritis be treated with a TNF-blocker?

  2010cites this paper